首页> 外文OA文献 >Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

【2h】

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

机译：目前授权的第二次或第三线治疗表皮生长因子受体（EGFR）的比较存活率和促进淋巴瘤激酶（ALK）阴性先进或转移性非小细胞癌：对试验的系统审查和次要分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Martin Connock; Xavier Armoiry; Alexander Tsertsvadze; G. J. Melendez-Torres; Pamela Royle; Lazaros Andronis; Aileen Clarke;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials [J] . Martin Connock, Xavier Armoiry, Alexander Tsertsvadze, BMC Cancer . 2019,第1期

机译：目前授权的第二次或第三线治疗表皮生长因子受体（EGFR）的比较存活率和促进淋巴瘤激酶（ALK）阴性先进或转移性非小细胞癌：对试验的系统审查和次要分析
2. A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer [J] . Gallacher Daniel, Auguste Peter, Royle Pamela, Clinical drug investigation . 2019,第12期

机译：对经济评估的系统审查，评估了用于先前经过治疗的表皮生长因子受体（EGFR）和促进淋巴瘤激酶（ALK）阴性晚期/转移性非小细胞肺癌的持牌药物的成本效益
3. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis [J] . Tingting Liu, Silu Ding, Jun Dang, Journal of Thoracic Disease . 2019,第7期

机译：具有野生型表皮生长因子受体（EGFR）或间变性淋巴瘤激酶（ALK）的晚期非小细胞肺癌的一线免疫检查点抑制剂：系统评价和网络荟萃分析
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials [O] . Martin Connock, Xavier Armoiry, Alexander Tsertsvadze, 2019

机译：当前许可的表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）阴性晚期或转移性非小细胞肺癌的二线或三线治疗的相对生存获益：系统评价和试验的二级分析
7. A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer [O] . Daniel Gallacher, Peter Auguste, Pamela Royle, 2019

机译：对经济评估的系统审查，评估了用于先前经过治疗的表皮生长因子受体（EGFR）和促进淋巴瘤激酶（ALK）阴性晚期/转移性非小细胞肺癌的持牌药物的成本效益

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

著录项

引文网络

相似文献

相关主题

期刊订阅